C-reactive protein level and microbial aetiology in patients hospitalised with acute exacerbation of COPD

European Respiratory Journal

Volumn 45, Issue 1, 2015, Pages 76-86

  Clark, Tristan W ^a,b   Medina, Marie Jo ^b   Batham, Sally ^b   Curran, Martin D ^c   Parmar, Surendra ^c   Nicholson, Karl G ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL ANTIGEN; C REACTIVE PROTEIN; INFLUENZA VACCINE; PNEUMOCOCCAL ANTIGEN; STEROID; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM DETECTION; BLOOD CULTURE; BLOOD SAMPLING; BODY TEMPERATURE; C REACTIVE PROTEIN BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; EXPLORATORY RESEARCH; FEMALE; HOSPITAL PATIENT; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NASOPHARYNGEAL SWAB; NONHUMAN; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RESPIRATORY VIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPUTUM CULTURE; THROAT CULTURE; URINALYSIS; VIRAL RESPIRATORY TRACT INFECTION; VIRUS DETECTION; COMPLICATION; HOSPITAL ADMISSION; HOSPITALIZATION; METABOLISM; MICROBIOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; REGRESSION ANALYSIS; SPUTUM; STREPTOCOCCUS INFECTION; VIRUS INFECTION;

AGED; BACTERIAL INFECTIONS; BIOMARKERS; BODY TEMPERATURE; C-REACTIVE PROTEIN; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT ADMISSION; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGRESSION ANALYSIS; SPUTUM; STREPTOCOCCAL INFECTIONS; VIRUS DISEASES;

EID: 84920565580     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00092214     Document Type: Article

References (34)

1. Stang P, Lydick E, Silberman C, et al. The prevalence of COPD: using smoking rates to estimate disease frequency in the general population. Chest 2000; 117: Suppl. 2, 354S-359S.
2. Niewoehner DE. The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. Am J Med 2006; 119: 38-45.
3. Hirschmann JV. Do bacteria cause exacerbations of COPD? Chest 2000; 118: 193-203
4. Sethi S, Sethi R, Eschberger K, et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 356-361.
5. Sethi S, Wrona C, Grant BJ, et al. Strain specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 448-453.
6. Sethi S, Wrona C, Eschberger K, et al. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 491-497.
7. Murphy TF, Brauer AL, Grant BJ, et al. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med 2005; 172: 195-199.
8. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355-2365.
9. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1618-1623.
10. Rohde G, Wiethege A, Borg I, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax 2003; 58: 37-42.
11. Kherad O, Kaiser L, Bridevaux PO, et al. Upper-respiratory viral infection, biomarkers, and COPD exacerbations. Chest 2010; 138: 896-904.
12. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173: 1114-1121.
13. Gunawardana N, Finney L, Johnston SL, et al. Experimental rhinovirus infection in COPD: implications for antiviral therapies. Antiviral Res 2014; 102: 95-105.
14. Wilkinson TM, Hurst JR, Perera W, et al. Effect of interaction of bacterial and rhinoviral infection during chronic obstructive pulmonary disease exacerbations. Chest 2006; 129: 317-324.
15. Molyneaux PL, Mallia P, Cox MJ, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 188: 1224-1231.
16. George SN, Garcha DS, Mackay AJ, et al. Human rhinovirus infection during naturally occurring COPD exacerbations. Eur Respir J 2014; 44: 87-96.
17. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174: 867-874.
18. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007; 131: 1058-1067.
19. Brämer GR. International statistical classification of diseases and related health problems. Tenth revision. World Health Stat Q 1988; 41: 32-36.
20. Hutchinson EC, Curran MD, Read EK, et al. Mutational analysis of cis-acting RNA signals in segment 7 of influenza A virus. J Virol 2008; 82: 11869-11879.
21. Ellis JS, Curran MD. Simultaneous molecular detection and confirmation of influenza A H5, with internal control. In: Stephenson JR, Warnes A, eds. Diagnostic Virology Protocols (Methods in Molecular Biology series). 2nd Edn. Totowa, NJ, Humana Press 2011; pp. 161-181.
22. Heim A, Ebnet C, Harste G, et al. Rapid and quantitative detection of human adenovirus DNA by real-time PCR. J Med Virol 2003; 70: 228-239.
23. Dare R, Sanghavi S, Bullotta A, et al. Diagnosis of human metapneumovirus infection in immunosuppressed lung transplant recipients and children evaluated for pertussis. J Clin Microbiol 2007; 45: 548-552.
24. Melbye H, Hvidsten D, Holm A, et al. The course of C-reactive protein response in untreated upper respiratory tract infection. Br J Gen Pract 2004; 54: 653-658.
25. Murphy TF, Brauer AL, Schiffmacher AT, et al. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 266.
26. Welte T, Miravitlles M. Viral, bacterial or both? Regardless, we need to treat infection in COPD. Eur Respir J 2014; 44: 11-13.
27. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184: 662-671.
28. Bozinovski S, Hutchinson A, Thompson M, et al. Serum amyloid A is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 269-278.
29. Vollenweider DJ, Jarrett H, Steurer-Stey CA, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 12: CD010257.
30. Garcha DS, Thurston SJ, Patel AR, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012; 67: 1075-1080.
31. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 2001; 14: 336-363.
32. Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 250-255.
33. Man SF, Connett JE, Anthonisen NR, et al. C reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006; 61: 849-853.
34. de Torres JP, Cordoba-Lanus E, López-Aguilar C, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006; 27: 902-907.